B6-huMSLN Mouse
Product Name
B6-huMSLN Mouse
Product ID
C001856
Strain Name
C57BL/6NCya-Mslntm1(hMSLN)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “B6-huMSLN Mouse (Catalog C001856) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
MSLN
Gene Alias
MPF, SMRP
NCBI ID
Chromosome
Chr 16 (Human)
MGI ID
Datasheet
Strain Description
The MSLN gene encodes a preproprotein that is proteolytically processed into two distinct proteins: megakaryocyte potentiating factor (MPF) and mesothelin [1]. MPF functions as a cytokine that promotes the formation of megakaryocytes in bone marrow, while mesothelin is a glycosylphosphatidylinositol-anchored cell-surface protein that may play a role in cell adhesion. While mesothelin expression is normally low and restricted to mesothelial cells lining the pleura, peritoneum, and pericardium, it is highly overexpressed in several epithelial cancers, including malignant mesothelioma, ovarian cancer, pancreatic cancer, and certain types of lung cancer [2-3]. This high expression and its function in promoting cell proliferation and metastasis make mesothelin a significant biomarker and a target for cancer therapies [4].
The B6-huMSLN mouse model was generated by replacing sequences from the ATG start codon to the TGA stop codon of the endogenous mouse Msln gene with the sequences from the ATG start codon to the TGA stop codon of the human MSLN gene. This model can be used to study the pathological mechanisms and therapeutic approaches for several cancers, including malignant mesothelioma, ovarian cancer, pancreatic cancer, and certain types of lung cancer, as well as for the development of MSLN-targeted drugs.
Reference
Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008 Jan;44(1):46-53.
Hagerty BL, Takabe K. Biology of Mesothelin and Clinical Implications: A Review of Existing Literature. World J Oncol. 2023 Oct;14(5):340-349.
Kosti P, Abram-Saliba J, Pericou-Troquier L, Pavelot S, Ruggeri T, Laffaille M, Irving M, Coukos G, Lanitis E, Dunn SM. Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager. J Immunother Cancer. 2025 Mar 13;13(3):e010063.
Kumari S. Mesothelin as a Signal Pathways and Epigenetic Target in Cancer Therapy. Cancers (Basel). 2025 Mar 26;17(7):1118.
Strain Strategy
The sequences from the ATG start codon to the TGA stop codon of the endogenous mouse Msln gene were replaced with the sequences from the ATG start codon to the TGA stop codon of the human MSLN gene.
Figure 1. Gene editing strategy of B6-huMSLN mice.
Application Area
MSLN-targeted drug screening, development, and evaluation;
Research on pathological mechanisms and therapeutic approaches for several cancers.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
